TOP TIERMARKET NEWSWIRE
Movers explained · 2026-11-18

Archived explainer. For the current picture see today's SLS page.

Why Is SELLAS LIFE SCIENCES (SLS) Stock Up Today?

By the Top Tier Newswire AI Desk · November 18, 2026 at 11:28 AM ET · reviewed against 31 wire stories

SELLAS LIFE SCIENCES (SLS) is up +7.81% in the latest session. Our newswire has captured 31 stories on SLS across 13 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Sellas Life Sciences (SLS) shares rose 7.81% to $20.65, driven by positive topline results from its pivotal Phase 3 REGAL trial for galinpepimut-s in acute myeloid leukemia. The stock rebounded sharply after opening lower on news of a new equity offering.

What Happened

The company announced the initiation of a public offering to sell $150 million in common stock on November 17, 2026. This capital raise followed the release of positive data from the REGAL trial, which demonstrated that the experimental cancer vaccine extended survival in patients with acute myeloid leukemia. The stock initially gapped down 5.1% to open at $18.18, reflecting a reaction to the dilution news, before reversing course to close at $20.65. The move places the stock near the top of its 52-week range, which spans from $1.39 to $24.89.

What The Data Shows

Trading volume reached 15.3 million shares, which is 2.3 times the three-month daily average. The session high was $21.16 at 9:30 AM ET, while the low was $17.22 at 9:40 AM ET. Over the last eight sessions, the stock has climbed 127.4%, moving from $8.42 to the prior close of $19.15. Unusual options activity included 12 notable prints, with call premium totaling $18.3 million compared to $8.0 million in put premium. The largest single print was $4.2 million. The company has a market cap of $1.5 billion and remains unprofitable with a trailing twelve-month EPS of -0.20. Its beta is 2.70. Retail traders on r/wallstreetbets expressed gratitude for the biotech rally, while social media chatter remained sparse with only one post in seven days.

What To Watch

The stock printed a fresh 52-week high and ten fresh 52-week lows on November 18, 2026. Investors will monitor how the market absorbs the $150 million capital raise and whether the strong trial results sustain the recent upward momentum.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

SLS by the numbers

Last: $20.65Session: +7.81%7 sessions: +109.21%Coverage: 31 stories / 13 sourcesAI sentiment: 60/100 (bullish)Mkt cap: $1.5B52w: $1.39 to $24.89
SLS · Nov 18 session (5-min) · -6.42% vs prior close · updated 8:53 PM ET
$17.27$19.27$21.27prev close $19.15$17.927:00 AM10:13 AM1:27 PM4:41 PM7:55 PM7:00 AM · $18.267:05 AM · $18.817:10 AM · $18.667:15 AM · $18.637:20 AM · $18.487:25 AM · $18.617:30 AM · $18.827:35 AM · $18.707:40 AM · $18.657:45 AM · $18.757:50 AM · $19.387:55 AM · $19.328:00 AM · $18.708:05 AM · $18.728:10 AM · $18.788:15 AM · $18.228:20 AM · $18.368:25 AM · $18.258:30 AM · $18.688:35 AM · $18.918:40 AM · $19.048:45 AM · $19.238:50 AM · $19.348:55 AM · $19.229:00 AM · $19.189:05 AM · $19.159:10 AM · $19.099:15 AM · $19.109:20 AM · $19.069:25 AM · $19.509:30 AM · $18.439:35 AM · $17.489:40 AM · $17.649:45 AM · $18.169:50 AM · $18.779:55 AM · $19.6210:00 AM · $19.5110:05 AM · $19.8110:10 AM · $20.2310:15 AM · $19.5510:20 AM · $19.6710:25 AM · $19.6310:30 AM · $19.6610:35 AM · $19.6810:40 AM · $19.5710:45 AM · $19.2110:50 AM · $19.3510:55 AM · $19.1711:00 AM · $19.4011:05 AM · $19.2911:10 AM · $19.2911:15 AM · $19.3411:20 AM · $20.2311:25 AM · $20.9511:30 AM · $21.0511:35 AM · $20.7611:40 AM · $20.6411:45 AM · $20.5111:50 AM · $20.3311:55 AM · $19.9712:00 PM · $20.0212:05 PM · $19.9212:10 PM · $19.8712:15 PM · $19.8512:20 PM · $19.9612:25 PM · $20.0112:30 PM · $20.3712:35 PM · $20.3312:40 PM · $20.2912:45 PM · $19.9512:50 PM · $20.0112:55 PM · $20.051:00 PM · $19.931:05 PM · $19.771:10 PM · $19.631:15 PM · $19.661:20 PM · $19.661:25 PM · $19.131:30 PM · $19.361:35 PM · $19.131:40 PM · $19.111:45 PM · $19.011:50 PM · $19.041:55 PM · $19.072:00 PM · $18.702:05 PM · $18.672:10 PM · $18.832:15 PM · $18.762:20 PM · $19.052:25 PM · $19.072:30 PM · $18.832:35 PM · $18.862:40 PM · $18.902:45 PM · $18.762:50 PM · $18.772:55 PM · $18.933:00 PM · $19.193:05 PM · $19.043:10 PM · $19.013:15 PM · $18.923:20 PM · $18.903:25 PM · $18.823:30 PM · $18.203:35 PM · $18.273:40 PM · $18.423:45 PM · $18.433:50 PM · $18.273:55 PM · $17.954:00 PM · $17.984:05 PM · $17.944:10 PM · $17.864:15 PM · $18.004:20 PM · $17.904:25 PM · $17.984:30 PM · $17.994:35 PM · $17.984:40 PM · $17.944:45 PM · $17.974:50 PM · $17.954:55 PM · $17.915:00 PM · $17.905:05 PM · $17.865:10 PM · $18.005:15 PM · $17.995:20 PM · $17.995:25 PM · $17.985:30 PM · $17.955:35 PM · $17.995:40 PM · $18.005:45 PM · $18.005:50 PM · $18.005:55 PM · $17.936:00 PM · $17.936:05 PM · $17.956:10 PM · $17.986:15 PM · $17.996:20 PM · $17.866:25 PM · $17.896:30 PM · $17.846:35 PM · $18.056:40 PM · $18.046:45 PM · $18.026:50 PM · $18.046:55 PM · $18.057:00 PM · $18.017:05 PM · $18.047:10 PM · $17.977:20 PM · $17.987:25 PM · $17.987:30 PM · $17.987:35 PM · $17.937:40 PM · $17.937:45 PM · $17.987:50 PM · $17.957:55 PM · $17.92
AI sentiment, last 36h · averaged over 31 stories · 60/100 bullish
AI sentiment 60/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishThe Fly · sentiment 26 · Sellas Life Sciences announces $150M common stock offeringThe Fly · 26Sellas Life Sciences announces $150M common stock offeringInvesting.com Markets · sentiment 50 · After-Hours Movers: NVDA, CRWV, NBIS, AAOI, SLSInvesting.com Markets · 50After-Hours Movers: NVDA, CRWV, NBIS, AAOI, SLSInvesting.com Markets · sentiment 26 · Sellas Life Sciences stock falls on $150M stock offeringInvesting.com Markets · 26Sellas Life Sciences stock falls on $150M stock offeringGuruFocus · sentiment 26 · SELLAS Life Sciences Group (SLS) Launches $150M Stock Offering Amid Biotech Growth ProspectsGuruFocus · 26SELLAS Life Sciences Group (SLS) Launches $150M Stock Offering Amid Biotech Growth ProspectsSeeking Alpha · sentiment 74 · SELLAS Life Sciences Group, Inc. (SLS) Discusses Positive Phase III REGAL Trial Results for Galinpepimut-S in Acute Myeloid Leukemia Prepared Remarks TranscriptSeeking Alpha · 74SELLAS Life Sciences Group, Inc. (SLS) Discusses Positive Phase III REGAL Trial Results f…MarketWatch · sentiment 28 · SELLAS Life Sciences Shares Down in Late Market After Public Offering NewsMarketWatch · 28SELLAS Life Sciences Shares Down in Late Market After Public Offering NewsStocktwits News · sentiment 74 · SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From HereStocktwits News · 74SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Gr…Stocktwits News · sentiment 58 · SLS And IBRX Share 3 Institutional Backers With Big Pharma Giants — As Stanley Druckenmiller Makes Bold Prediction: ‘We’re Gonna Beat Cancer’Stocktwits News · 58SLS And IBRX Share 3 Institutional Backers With Big Pharma Giants — As Stanley Druckenmil…
2d agoStocktwits NewsBULLISH 58General

SLS And IBRX Share 3 Institutional Backers With Big Pharma Giants — As Stanley Druckenmiller Makes Bold Prediction: ‘We’re Gonna Beat Cancer’

New York’s pension fund held $1.42 billion in the three pharma giants versus just under $2 million in SLS and IBRX.

2d agoStocktwits NewsBULLISH 74General

SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here

A $1,000 investment in SLS at the end of 2025 was worth about $5,080 at Tuesday’s close.

2d agoMarketWatchBEARISH 28General

SELLAS Life Sciences Shares Down in Late Market After Public Offering News

2d agoSeeking AlphaBULLISH 74Product/PR

SELLAS Life Sciences Group, Inc. (SLS) Discusses Positive Phase III REGAL Trial Results for Galinpepimut-S in Acute Myeloid Leukemia Prepared Remarks Transcript

SELLAS Life Sciences Group, Inc. (SLS) Discusses Positive Phase III REGAL Trial Results for Galinpepimut-S in Acute Myeloid Leukemia November 17, 2026 7:45...

2d agoGuruFocusBEARISH 26General

SELLAS Life Sciences Group (SLS) Launches $150M Stock Offering Amid Biotech Growth Prospects

On November 17, 2026, SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced the initiation of a public offering to sell $150 million in common stock, with an u

2d agoInvesting.com MarketsBEARISH 26General

Sellas Life Sciences stock falls on $150M stock offering

Sellas Life Sciences stock falls on $150M stock offering

2d agoInvesting.com MarketsNEUTRAL 50General

After-Hours Movers: NVDA, CRWV, NBIS, AAOI, SLS

After-Hours Movers: NVDA, CRWV, NBIS, AAOI, SLS

2d agoThe FlyBEARISH 26General

Sellas Life Sciences announces $150M common stock offering

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on SLS: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier SLS move explainers: 2026-11-20 · 2026-11-19 · 2026-11-18 · 2026-11-17 · 2026-11-13 · 2026-10-28 · 2026-10-20 · 2026-10-19 · 2026-08-31 · 2026-08-28 · 2026-08-27 · 2026-08-25 · 2026-08-24 · 2026-08-21 · 2026-08-17